Vaxcyte Inc
PCVXHealthcare|Biotechnology|USA
$58.20
-1.62 (-2.71%)
Tangible Book
$20.76
Earnings Power
$7.32
Upcoming Data Readouts (5)
Jan 2027
Est. completion
P3Pneumococcal Vaccines
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
NCT07284654n=4,049
Mar 2027
Est. completion
P3Pneumococcal Vaccines
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
NCT07365826n=1,390
Mar 2027
Est. completion
P3Pneumococcal Vaccines
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
NCT07425392n=752
Dec 2027
Est. completion
P1Group A Streptococcal Infection
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
NCT07616934n=80
Dec 2027
Est. completion
P2Pneumococcal Vaccines
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
NCT06720038n=900